晚期胃癌有救了？全球首个实体瘤CAR-T来了
Ranking
No observed public metrics; popularity remains neutral/archived.
Merged summary
TL;DR - China approved and began clinically deploying satricabtagene autoleucel (舒瑞基奥仑赛注射液), the world's first autologous CAR-T therapy for a solid tumor, targeting CLDN18.2-positive/HER2-negative advanced gastric cancer after ≥2 lines of failed treatment. It breaks the long-standing barrier that confined CAR-T to blood cancers, but at ¥990,000 per dose it raises hard access/payment questions.
- Pivotal Phase II (Lancet, May 2025; 156 patients across 24 hospitals, 2:1 randomization): median PFS 3.25 vs 1.77 months (63% risk reduction), median OS 7.92 vs 5.49 months (31% risk reduction). Because of crossover design, a treated-vs-never-treated comparison showed median OS 9.17 vs 3.98 months; early "favorable-profile" patients had 57–61% response rates, one patient exceeded 40 months OS.
- Solid-tumor engineering hurdles addressed: dense fibrotic stroma blocking T-cell infiltration, hypoxic/immunosuppressive tumor microenvironment, and on-target/off-tumor toxicity since CLDN18.2 is expressed in normal gastric mucosa. Mitigations included early apheresis while patients are still fit, CAR construct design for safety, and low-dose nab-paclitaxel to soften the fibrous matrix and improve CAR-T penetration.
- CLDN18.2 is also expressed in pancreatic and esophageal cancers, so the validated route may extend to other GI solid tumors; the team has already treated several first-line gastric cancer patients (all responding) and is seeking funding for frontline expansion, with patient selection (bone metastases, high liver burden respond poorly) as the main challenge.
- Access economics: single-administration dosing is the key advantage over competing CLDN18.2 mAbs/bispecifics/ADCs (zolbetuximab, ASKB-589, FG-M108, LM-302), and the developer argues total cost is comparable to a year of antibody therapy; China's first commercial-insurance innovative-drug catalogue (2025) includes 5 hematologic CAR-Ts, but experts note the payment pool is small and suggest European-style milestone-based, outcome-contingent installment payments.
Sources (1)
晚期胃癌有救了？全球首个实体瘤CAR-T来了
TL;DR - China approved and began clinically deploying satricabtagene autoleucel (舒瑞基奥仑赛注射液), the world's first autologous CAR-T therapy for a solid tumor, targeting CLDN18.2-positive/HER2-negative advanced gastric cancer after ≥2 lines of failed treatment. It breaks the long-standing barrier that confined CAR-T to blood cancers, but at ¥990,000 per dose it raises hard access/payment questions.
- Pivotal Phase II (Lancet, May 2025; 156 patients across 24 hospitals, 2:1 randomization): median PFS 3.25 vs 1.77 months (63% risk reduction), median OS 7.92 vs 5.49 months (31% risk reduction). Because of crossover design, a treated-vs-never-treated comparison showed median OS 9.17 vs 3.98 months; early "favorable-profile" patients had 57–61% response rates, one patient exceeded 40 months OS.
- Solid-tumor engineering hurdles addressed: dense fibrotic stroma blocking T-cell infiltration, hypoxic/immunosuppressive tumor microenvironment, and on-target/off-tumor toxicity since CLDN18.2 is expressed in normal gastric mucosa. Mitigations included early apheresis while patients are still fit, CAR construct design for safety, and low-dose nab-paclitaxel to soften the fibrous matrix and improve CAR-T penetration.
- CLDN18.2 is also expressed in pancreatic and esophageal cancers, so the validated route may extend to other GI solid tumors; the team has already treated several first-line gastric cancer patients (all responding) and is seeking funding for frontline expansion, with patient selection (bone metastases, high liver burden respond poorly) as the main challenge.
- Access economics: single-administration dosing is the key advantage over competing CLDN18.2 mAbs/bispecifics/ADCs (zolbetuximab, ASKB-589, FG-M108, LM-302), and the developer argues total cost is comparable to a year of antibody therapy; China's first commercial-insurance innovative-drug catalogue (2025) includes 5 hematologic CAR-Ts, but experts note the payment pool is small and suggest European-style milestone-based, outcome-contingent installment payments.